MANKIND - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.7
| Stock Code | MANKIND | Market Cap | 99,749 Cr. | Current Price | 2,414 ₹ | High / Low | 2,727 ₹ |
| Stock P/E | 47.0 | Book Value | 397 ₹ | Dividend Yield | 0.04 % | ROCE | 13.6 % |
| ROE | 13.7 % | Face Value | 1.00 ₹ | DMA 50 | 2,331 ₹ | DMA 200 | 2,290 ₹ |
| Chg in FII Hold | -1.10 % | Chg in DII Hold | 1.20 % | PAT Qtr | 732 Cr. | PAT Prev Qtr | 512 Cr. |
| RSI | 56.4 | MACD | 9.80 | Volume | 4,99,300 | Avg Vol 1Wk | 3,94,691 |
| Low price | 1,910 ₹ | High price | 2,727 ₹ | PEG Ratio | 2.32 | Debt to equity | 0.34 |
| 52w Index | 61.8 % | Qtr Profit Var | 207 % | EPS | 49.4 ₹ | Industry PE | 32.5 |
📊 Analysis: Mankind Pharma (MANKIND) shows moderate fundamentals with ROE at 13.7% and ROCE at 13.6%, reflecting average capital efficiency. Valuation is stretched with a P/E of 47.0 compared to the industry average of 32.5. The [PEG ratio](ca://s?q=Explain_PEG_ratio) of 2.32 indicates growth is not sufficient to justify the premium. Dividend yield is negligible at 0.04%, limiting income support. Technicals show the stock trading above [DMA 50](ca://s?q=Explain_DMA_in_stocks) (2,331 ₹) and [DMA 200](ca://s?q=Explain_DMA_in_stocks) (2,290 ₹), with RSI at 56.4 suggesting neutral momentum. Quarterly PAT surged (732 Cr vs 512 Cr), reflecting strong earnings growth, though valuations remain high.
💡 Entry Price Zone: Ideal accumulation range is 2,250–2,350 ₹, aligning with DMA levels. Current price (2,414 ₹) is slightly above this zone, making cautious entry advisable.
📈 Exit / Holding Strategy: If already holding, maintain a medium-to-long horizon (3–5 years). Monitor quarterly PAT trends and ROE improvement. Exit partially near 2,650–2,700 ₹ resistance if earnings stagnate. Long-term compounding potential depends on sustained profitability and valuation moderation.
✅ Positive
- 📌 EPS at 49.4 ₹ reflects profitability.
- 📌 Quarterly PAT surged (732 Cr vs 512 Cr), showing strong earnings momentum.
- 📌 DII holdings increased (+1.20%), showing domestic institutional confidence.
- 📌 Debt-to-equity ratio at 0.34, indicating manageable leverage.
⚠️ Limitation
- 📌 High [P/E ratio](ca://s?q=What_is_PE_ratio) (47.0 vs industry 32.5).
- 📌 Elevated [PEG ratio](ca://s?q=Explain_PEG_ratio) (2.32), showing poor valuation-to-growth alignment.
- 📌 Very low [dividend yield](ca://s?q=Dividend_yield_explained) (0.04%).
📉 Company Negative News
- 📌 FII holdings decreased (-1.10%), showing reduced foreign investor confidence.
📈 Company Positive News
- 📌 Quarterly profit variation (+207%) highlights strong operational growth.
- 📌 Stock trading above DMA 50 and DMA 200, showing technical strength.
🏭 Industry
- 📌 Pharma sector average P/E is 32.5, lower than Mankind Pharma’s valuation.
- 📌 Industry growth remains steady, driven by demand for generics and specialty medicines.
🔎 Conclusion
Mankind Pharma is fundamentally stable but overvalued compared to industry peers, making it a cautious candidate for long-term investment. Ideal entry is 2,250–2,350 ₹, aligning with technical support. Existing holders may continue with a 3–5 year horizon, but partial profit booking near 2,650–2,700 ₹ is advisable unless earnings growth strengthens and valuations moderate.